MALT1 inhibitor MI-2
Based on 7 publication(s) in Google Scholar
MALT1 inhibitor MI-2 is a MALT1 inhibitor (IC50=5.84 μM). MALT1 inhibitor MI-2 binds directly to MALT1, irreversibly suppresses protease function and is accompanied by NF-κB reporter activity suppression, c-REL nuclear localization inhibition, and NF-κB target gene downregulation. MALT1 inhibitor MI-2 shows nontoxic to animals.
For research use only. We do not sell to patients.
- Purity: 99.73%
- CAS No.: 1047953-91-2
- Formula: C19H17Cl3N4O3
- Molecular Weight:455.72
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
NF-κB Signaling Compound Library
HY-L014
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Targeted Diversity Library
HY-L099
-
Protease Inhibitor Library
HY-L147
-
Cysteine Targeted Covalent Library
HY-L153
-
MCE Bioactive Compound Library
HY-L001V
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) MALT1 inhibitor MI-2
More- Nat Cancer. 2025 Apr;6(4):702-717. [Abstract]
- Hemasphere. 2025 Mar 17;9(3):e70098. [Abstract]
- Blood Adv. 2024 Aug 13;8(15):4003-4016. [Abstract]
- Front Microbiol. 2021 Feb 2;12:607451. [Abstract]
- J Virol. 2019 Nov 26;93(24):e01499-19. [Abstract]
- Parasit Vectors. 2018 May 18;11(1):305. [Abstract]
- bioRxiv. 2023 Jul 11:2023.07.07.548031. [Abstract]
Customer Validation & Images
-
WB
Biological Activity
IC50: 5.84 μM (MALT1)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| OCI-Ly3 | IC50 |
2.6 μM
Compound: MI-2
|
Antiproliferative activity against human OCI-LY3 cells after 48 hrs by MTT assay
Antiproliferative activity against human OCI-LY3 cells after 48 hrs by MTT assay
|
[PMID: 26496175] |
| Toledo | IC50 |
0.8 μM
Compound: 11; MI-2
|
Antiproliferative activity against human Toledo cells after 48 hrs by CCK8 assay
Antiproliferative activity against human Toledo cells after 48 hrs by CCK8 assay
|
[PMID: 29751989] |
MALT1 inhibitor MI-2 (1-1000 nM; 48 hours) selectively suppresses MALT1-dependent DLBCL cell lines, and the GI50 in HBL-1, TMD8, OCI-Ly3, and OCI-Ly10 cells is 0.2, 0.5, 0.4, and 0.4 μM, respectively[1].
MALT1 inhibitor MI-2 (62-1000 nM; 24 hours) causes a dose-dependent decrease in MALT1-mediated cleavage[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HBL-1, TMD8, OCI-Ly3, OCI-Ly10 cells
-
Concentration:1, 10, 100, 1000 nM
-
Incubation Time:48 hours
-
Result:The GI50 in HBL-1, TMD8, OCI-Ly3, and OCI-Ly10 cells was 0.2, 0.5, 0.4, and 0.4 µM, respectively.
-
Cell Line:HBL-1 cells
-
Concentration:62, 125, 250, 500, 1000 nM
-
Incubation Time:24 hours
-
Result:Inhibits MALT1 cleavage of CYLD in HBL-1 cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Eight-week-old male SCID NOD (bearing HBL-1 and TMD8 cells)[1]
-
Dosage:25 mg/kg
-
Administration:Intraperitoneal injection; daily for 14 days
-
Result:Profoundly suppressed the growth of both the TMD8 and HBL-1 ABC-DLBCL xenografts versus vehicle.
Chemical Information
-
CAS No. 1047953-91-2
-
Appearance Solid
-
Molecular Weight 455.72
-
Formula C19H17Cl3N4O3
-
Color White to off-white
-
SMILES
O=C(NC1=CC=C(N2N=C(OCCOC)N=C2C3=CC=C(Cl)C(Cl)=C3)C=C1)CCl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Nat Cancer
Targeting both death and paracaspase domains of MALT1 with antisense oligonucleotides overcomes resistance to immune-checkpoint inhibitors. [Abstract]2025 Apr;6(4):702-717. PMID: 40075237 -
Hemasphere
2025 Mar 17;9(3):e70098. PMID: 40098895 -
Blood Adv
Halting Multiple Myeloma with MALT1 Inhibition: Suppressing BCMA-Induced NF-κB and Inducing Immunogenic Cell Death. [Abstract]2024 Aug 13;8(15):4003-4016. PMID: 38820414 -
Front Microbiol
Cellular CARD11 Inhibits the Fusogenic Activity of Newcastle Disease Virus via CBM Signalosome-Mediated Furin Reduction in Chicken Fibroblasts. [Abstract]2021 Feb 2;12:607451. PMID: 33603723 -
J Virol
Host CARD11 Inhibits Newcastle Disease Virus Replication by Suppressing Viral Polymerase Activity in Neurons. [Abstract]2019 Nov 26;93(24):e01499-19. PMID: 31554683 -
Parasit Vectors
The Toxoplasma gondii ME-49 strain upregulates levels of A20 that inhibit NF-κB activation and promotes apoptosis in human leukaemia T-cell lines. [Abstract]2018 May 18;11(1):305. PMID: 29776374
MALT1 inhibitor MI-2 purchased from MedChemExpress. Usage Cited in: Parasit Vectors. 2018 May 18;11(1):305. [Abstract]
The A20 protein levels in Jurkat T-cells and Molt-4 T-cells treated with MALT1 inhibitor MI-2 and combined use of MI-2 and ME-49.
-
bioRxiv
Transcriptional regulation of amino acid metabolism by KDM2B, in the context of ncPRC1.1 and in concert with MYC and ATF4. [Abstract]2023 Jul 11:2023.07.07.548031. PMID: 37461630
Solvent & Solubility
DMSO : ≥ 46 mg/mL (100.94 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.49 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1943 mL | 10.9716 mL | 21.9433 mL | 54.8582 mL |
| 5 mM | 0.4389 mL | 2.1943 mL | 4.3887 mL | 10.9716 mL | |
| 10 mM | 0.2194 mL | 1.0972 mL | 2.1943 mL | 5.4858 mL | |
| 15 mM | 0.1463 mL | 0.7314 mL | 1.4629 mL | 3.6572 mL | |
| 20 mM | 0.1097 mL | 0.5486 mL | 1.0972 mL | 2.7429 mL | |
| 25 mM | 0.0878 mL | 0.4389 mL | 0.8777 mL | 2.1943 mL | |
| 30 mM | 0.0731 mL | 0.3657 mL | 0.7314 mL | 1.8286 mL | |
| 40 mM | 0.0549 mL | 0.2743 mL | 0.5486 mL | 1.3715 mL | |
| 50 mM | 0.0439 mL | 0.2194 mL | 0.4389 mL | 1.0972 mL | |
| 60 mM | 0.0366 mL | 0.1829 mL | 0.3657 mL | 0.9143 mL | |
| 80 mM | 0.0274 mL | 0.1371 mL | 0.2743 mL | 0.6857 mL | |
| 100 mM | 0.0219 mL | 0.1097 mL | 0.2194 mL | 0.5486 mL |
MALT1 inhibitor MI-2 Related Classifications
HY-12276 Related Classifications
Powered by Bioz